[G24-35] Alectinib (NSCLC, adjuvant) – 2nd Addendum to Project A24-73
Last updated 16.01.2025
Project no.:
G24-35
Commission:
Commission awarded on 26.11.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
DOI:
https://doi.org/10.60584/G24-35
| Project no. | Title | Status |
|---|---|---|
| A24-73 | Alectinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-01-16 A G-BA decision was published.